Department of Mathematics, Universidad de Cádiz, Puerto Real, 11510 Cádiz, Spain.
Biomedical Research and Innovation Institute of Cádiz (INiBICA), Hospital Universitario Puerta del Mar, 11009 Cádiz, Spain.
Int J Mol Sci. 2021 Jun 14;22(12):6371. doi: 10.3390/ijms22126371.
Chimeric Antigen Receptor (CAR) T-cell therapy has demonstrated high rates of response in recurrent B-cell Acute Lymphoblastic Leukemia in children and young adults. Despite this success, a fraction of patients' experience relapse after treatment. Relapse is often preceded by recovery of healthy B cells, which suggests loss or dysfunction of CAR T-cells in bone marrow. This site is harder to access, and thus is not monitored as frequently as peripheral blood. Understanding the interplay between B cells, leukemic cells, and CAR T-cells in bone marrow is paramount in ascertaining the causes of lack of response. In this paper, we put forward a mathematical model representing the interaction between constantly renewing B cells, CAR T-cells, and leukemic cells in the bone marrow. Our model accounts for the maturation dynamics of B cells and incorporates effector and memory CAR T-cells. The model provides a plausible description of the dynamics of the various cellular compartments in bone marrow after CAR T infusion. After exploration of the parameter space, we found that the dynamics of CAR T product and disease were independent of the dose injected, initial B-cell load, and leukemia burden. We also show theoretically the importance of CAR T product attributes in determining therapy outcome, and have studied a variety of possible response scenarios, including second dosage schemes. We conclude by setting out ideas for the refinement of the model.
嵌合抗原受体 (CAR) T 细胞疗法在儿童和年轻成人复发性 B 细胞急性淋巴细胞白血病中显示出高反应率。尽管取得了这一成功,但仍有一部分患者在治疗后复发。复发通常先于健康 B 细胞的恢复,这表明 CAR T 细胞在骨髓中丢失或功能失调。骨髓部位较难触及,因此不像外周血那样频繁监测。了解骨髓中 B 细胞、白血病细胞和 CAR T 细胞之间的相互作用对于确定缺乏反应的原因至关重要。在本文中,我们提出了一个数学模型,该模型代表了骨髓中不断更新的 B 细胞、CAR T 细胞和白血病细胞之间的相互作用。我们的模型考虑了 B 细胞的成熟动力学,并纳入了效应器和记忆 CAR T 细胞。该模型为 CAR T 输注后骨髓中各种细胞区室的动力学提供了合理的描述。在探索参数空间后,我们发现 CAR T 产品和疾病的动力学与注射剂量、初始 B 细胞负荷和白血病负担无关。我们还从理论上展示了 CAR T 产品属性在确定治疗结果中的重要性,并研究了各种可能的反应情况,包括二次剂量方案。最后,我们提出了改进模型的思路。